Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Global Therapeutic Vaccines Market by Product (Autoimmune Disease Vaccines, Neurological Disease Vaccines, Cancer Vaccines, Infectious Disease Vaccines, Others) , by Technology (Allogeneic Vaccine, Autologous Vaccine) : Global Opportunity Analysis and Industry Forecast, 2024-2033

A00074

Pages: 300

Charts: 56

Tables: 112

Global Therapeutic Vaccines Market Research, 2033

The global global therapeutic vaccines market size was valued at $26.7 billion in 2023 and is projected to reach $135.7 billion by 2033, growing at a CAGR of 19.1% from 2024 to 2033.

Market Introduction and Definition

A therapeutic vaccination is one that is given after a sickness or infection has already been developed. A therapeutic vaccine activates a patient's immune system to fight against an infection. A therapeutic vaccine varies from a prophylactic vaccination. Prophylactic vaccines are given to people as a preventative strategy to avert infection or disease, whereas therapeutic vaccines are given after the person has been impacted by the sickness or infection. A therapeutic vaccination treats an existing infection in the body rather than immunizing it against future diseases and infections. Therapeutic vaccinations are mostly used against viral illnesses. Patients with chronic viral infections are provided therapeutic vaccinations because their immune system is unable to produce enough efficient antibodies.

Key Takeaways

  • The therapeutic vaccines market growth study covers 20 countries. The research includes a segment analysis of each country in terms of value ($billion) for the projected period from 2024 to 2033.
  • More than 1, 500 product literatures, industry releases, annual reports, and other such documents of major energy storage system industry participants along with authentic industry journals, trade associations' releases, and government websites have been reviewed for generating high-value industry insights.
  • The study integrates high-quality data, professional opinions and analysis, and critical independent perspectives. The research approach intends to provide a balanced view of global markets and assist stakeholders in making informed decisions in order to achieve their most ambitious growth objectives.

 Key Market Segments

  • By Product
    • Autoimmune Disease Vaccines
    • Neurological Disease Vaccines
    • Cancer Vaccines
    • Infectious Disease Vaccines
    • Others
  • By Technology
    • Allogeneic Vaccine
    • Autologous Vaccine
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • UAE
      • Rest of LAMEA

 
Key Market Players

  • Argos Therapeutics, Inc.
  • Merck & Co. Inc.
  • BioNTech SE
  • Novartis AG
  • Pfizer, Inc.
  • GSK plc.
  • AstraZeneca
  • Celldex Therapeutics Inc.
  • Dendreon Pharmaceuticals LLC
  • Agenus Inc.

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: THERAPEUTIC VACCINES MARKET, BY PRODUCT

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product

    • 4.2. Autoimmune Disease Vaccines

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Neurological Disease Vaccines

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Cancer Vaccines

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Infectious Disease Vaccines

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Others

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By Technology

    • 5.2. Allogeneic Vaccine

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Autologous Vaccine

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

  • CHAPTER 6: THERAPEUTIC VACCINES MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product

      • 6.2.3. Market Size and Forecast, By Technology

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Therapeutic Vaccines Market

        • 6.2.5.1. Market Size and Forecast, By Product
        • 6.2.5.2. Market Size and Forecast, By Technology

      • 6.2.6. Canada Therapeutic Vaccines Market

        • 6.2.6.1. Market Size and Forecast, By Product
        • 6.2.6.2. Market Size and Forecast, By Technology

      • 6.2.7. Mexico Therapeutic Vaccines Market

        • 6.2.7.1. Market Size and Forecast, By Product
        • 6.2.7.2. Market Size and Forecast, By Technology

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product

      • 6.3.3. Market Size and Forecast, By Technology

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Therapeutic Vaccines Market

        • 6.3.5.1. Market Size and Forecast, By Product
        • 6.3.5.2. Market Size and Forecast, By Technology

      • 6.3.6. Germany Therapeutic Vaccines Market

        • 6.3.6.1. Market Size and Forecast, By Product
        • 6.3.6.2. Market Size and Forecast, By Technology

      • 6.3.7. Italy Therapeutic Vaccines Market

        • 6.3.7.1. Market Size and Forecast, By Product
        • 6.3.7.2. Market Size and Forecast, By Technology

      • 6.3.8. Spain Therapeutic Vaccines Market

        • 6.3.8.1. Market Size and Forecast, By Product
        • 6.3.8.2. Market Size and Forecast, By Technology

      • 6.3.9. UK Therapeutic Vaccines Market

        • 6.3.9.1. Market Size and Forecast, By Product
        • 6.3.9.2. Market Size and Forecast, By Technology

      • 6.3.10. Russia Therapeutic Vaccines Market

        • 6.3.10.1. Market Size and Forecast, By Product
        • 6.3.10.2. Market Size and Forecast, By Technology

      • 6.3.11. Rest Of Europe Therapeutic Vaccines Market

        • 6.3.11.1. Market Size and Forecast, By Product
        • 6.3.11.2. Market Size and Forecast, By Technology

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product

      • 6.4.3. Market Size and Forecast, By Technology

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Therapeutic Vaccines Market

        • 6.4.5.1. Market Size and Forecast, By Product
        • 6.4.5.2. Market Size and Forecast, By Technology

      • 6.4.6. Japan Therapeutic Vaccines Market

        • 6.4.6.1. Market Size and Forecast, By Product
        • 6.4.6.2. Market Size and Forecast, By Technology

      • 6.4.7. India Therapeutic Vaccines Market

        • 6.4.7.1. Market Size and Forecast, By Product
        • 6.4.7.2. Market Size and Forecast, By Technology

      • 6.4.8. South Korea Therapeutic Vaccines Market

        • 6.4.8.1. Market Size and Forecast, By Product
        • 6.4.8.2. Market Size and Forecast, By Technology

      • 6.4.9. Australia Therapeutic Vaccines Market

        • 6.4.9.1. Market Size and Forecast, By Product
        • 6.4.9.2. Market Size and Forecast, By Technology

      • 6.4.10. Thailand Therapeutic Vaccines Market

        • 6.4.10.1. Market Size and Forecast, By Product
        • 6.4.10.2. Market Size and Forecast, By Technology

      • 6.4.11. Malaysia Therapeutic Vaccines Market

        • 6.4.11.1. Market Size and Forecast, By Product
        • 6.4.11.2. Market Size and Forecast, By Technology

      • 6.4.12. Indonesia Therapeutic Vaccines Market

        • 6.4.12.1. Market Size and Forecast, By Product
        • 6.4.12.2. Market Size and Forecast, By Technology

      • 6.4.13. Rest of Asia Pacific Therapeutic Vaccines Market

        • 6.4.13.1. Market Size and Forecast, By Product
        • 6.4.13.2. Market Size and Forecast, By Technology

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product

      • 6.5.3. Market Size and Forecast, By Technology

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Therapeutic Vaccines Market

        • 6.5.5.1. Market Size and Forecast, By Product
        • 6.5.5.2. Market Size and Forecast, By Technology

      • 6.5.6. South Africa Therapeutic Vaccines Market

        • 6.5.6.1. Market Size and Forecast, By Product
        • 6.5.6.2. Market Size and Forecast, By Technology

      • 6.5.7. Saudi Arabia Therapeutic Vaccines Market

        • 6.5.7.1. Market Size and Forecast, By Product
        • 6.5.7.2. Market Size and Forecast, By Technology

      • 6.5.8. UAE Therapeutic Vaccines Market

        • 6.5.8.1. Market Size and Forecast, By Product
        • 6.5.8.2. Market Size and Forecast, By Technology

      • 6.5.9. Argentina Therapeutic Vaccines Market

        • 6.5.9.1. Market Size and Forecast, By Product
        • 6.5.9.2. Market Size and Forecast, By Technology

      • 6.5.10. Rest of LAMEA Therapeutic Vaccines Market

        • 6.5.10.1. Market Size and Forecast, By Product
        • 6.5.10.2. Market Size and Forecast, By Technology

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Agenus Inc.

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Argos Therapeutics, Inc.

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Celldex Therapeutics Inc.

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Dendreon Pharmaceuticals LLC

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. GSK Plc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Merck And Co. Inc.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Novartis AG

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Pfizer, Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. AstraZeneca

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. BioNTech SE

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL THERAPEUTIC VACCINES MARKET, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL THERAPEUTIC VACCINES MARKET FOR AUTOIMMUNE DISEASE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL THERAPEUTIC VACCINES MARKET FOR NEUROLOGICAL DISEASE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL THERAPEUTIC VACCINES MARKET FOR CANCER VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL THERAPEUTIC VACCINES MARKET FOR INFECTIOUS DISEASE VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL THERAPEUTIC VACCINES MARKET FOR OTHERS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL THERAPEUTIC VACCINES MARKET, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL THERAPEUTIC VACCINES MARKET FOR ALLOGENEIC VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL THERAPEUTIC VACCINES MARKET FOR AUTOLOGOUS VACCINE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL THERAPEUTIC VACCINES MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. NORTH AMERICA THERAPEUTIC VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 14. U.S. THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 15. U.S. THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 16. CANADA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 17. CANADA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 18. MEXICO THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 20. EUROPE THERAPEUTIC VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 23. FRANCE THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 25. GERMANY THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 27. ITALY THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 28. ITALY THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 29. SPAIN THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 31. UK THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 32. UK THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 33. RUSSIA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 35. REST OF EUROPE THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 37. ASIA-PACIFIC THERAPEUTIC VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 40. CHINA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 41. CHINA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 42. JAPAN THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 44. INDIA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 45. INDIA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 46. SOUTH KOREA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 48. AUSTRALIA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 50. THAILAND THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 52. MALAYSIA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 54. INDONESIA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 56. REST OF ASIA PACIFIC THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 58. LAMEA THERAPEUTIC VACCINES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 61. BRAZIL THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 63. SOUTH AFRICA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 65. SAUDI ARABIA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 67. UAE THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 68. UAE THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 69. ARGENTINA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 71. REST OF LAMEA THERAPEUTIC VACCINES, BY PRODUCT, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA THERAPEUTIC VACCINES, BY TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 73. AGENUS INC.: KEY EXECUTIVES
  • TABLE 74. AGENUS INC.: COMPANY SNAPSHOT
  • TABLE 75. AGENUS INC.: OPERATING SEGMENTS
  • TABLE 76. AGENUS INC.: PRODUCT PORTFOLIO
  • TABLE 77. AGENUS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 78. ARGOS THERAPEUTICS, INC.: KEY EXECUTIVES
  • TABLE 79. ARGOS THERAPEUTICS, INC.: COMPANY SNAPSHOT
  • TABLE 80. ARGOS THERAPEUTICS, INC.: OPERATING SEGMENTS
  • TABLE 81. ARGOS THERAPEUTICS, INC.: PRODUCT PORTFOLIO
  • TABLE 82. ARGOS THERAPEUTICS, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 83. CELLDEX THERAPEUTICS INC.: KEY EXECUTIVES
  • TABLE 84. CELLDEX THERAPEUTICS INC.: COMPANY SNAPSHOT
  • TABLE 85. CELLDEX THERAPEUTICS INC.: OPERATING SEGMENTS
  • TABLE 86. CELLDEX THERAPEUTICS INC.: PRODUCT PORTFOLIO
  • TABLE 87. CELLDEX THERAPEUTICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 88. DENDREON PHARMACEUTICALS LLC: KEY EXECUTIVES
  • TABLE 89. DENDREON PHARMACEUTICALS LLC: COMPANY SNAPSHOT
  • TABLE 90. DENDREON PHARMACEUTICALS LLC: OPERATING SEGMENTS
  • TABLE 91. DENDREON PHARMACEUTICALS LLC: PRODUCT PORTFOLIO
  • TABLE 92. DENDREON PHARMACEUTICALS LLC: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 93. GSK PLC.: KEY EXECUTIVES
  • TABLE 94. GSK PLC.: COMPANY SNAPSHOT
  • TABLE 95. GSK PLC.: OPERATING SEGMENTS
  • TABLE 96. GSK PLC.: PRODUCT PORTFOLIO
  • TABLE 97. GSK PLC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 98. MERCK AND CO. INC.: KEY EXECUTIVES
  • TABLE 99. MERCK AND CO. INC.: COMPANY SNAPSHOT
  • TABLE 100. MERCK AND CO. INC.: OPERATING SEGMENTS
  • TABLE 101. MERCK AND CO. INC.: PRODUCT PORTFOLIO
  • TABLE 102. MERCK AND CO. INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 103. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 104. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 105. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 106. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 107. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 108. PFIZER, INC.: KEY EXECUTIVES
  • TABLE 109. PFIZER, INC.: COMPANY SNAPSHOT
  • TABLE 110. PFIZER, INC.: OPERATING SEGMENTS
  • TABLE 111. PFIZER, INC.: PRODUCT PORTFOLIO
  • TABLE 112. PFIZER, INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 113. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 114. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 115. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 116. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 117. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 118. BIONTECH SE: KEY EXECUTIVES
  • TABLE 119. BIONTECH SE: COMPANY SNAPSHOT
  • TABLE 120. BIONTECH SE: OPERATING SEGMENTS
  • TABLE 121. BIONTECH SE: PRODUCT PORTFOLIO
  • TABLE 122. BIONTECH SE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL THERAPEUTIC VACCINES MARKET SEGMENTATION
  • FIGURE 2. GLOBAL THERAPEUTIC VACCINES MARKET
  • FIGURE 3. SEGMENTATION THERAPEUTIC VACCINES MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN THERAPEUTIC VACCINES MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALTHERAPEUTIC VACCINES MARKET
  • FIGURE 11. THERAPEUTIC VACCINES MARKET SEGMENTATION, BY BY PRODUCT
  • FIGURE 12. THERAPEUTIC VACCINES MARKET FOR AUTOIMMUNE DISEASE VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. THERAPEUTIC VACCINES MARKET FOR NEUROLOGICAL DISEASE VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. THERAPEUTIC VACCINES MARKET FOR CANCER VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. THERAPEUTIC VACCINES MARKET FOR INFECTIOUS DISEASE VACCINES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. THERAPEUTIC VACCINES MARKET FOR OTHERS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. THERAPEUTIC VACCINES MARKET SEGMENTATION, BY BY TECHNOLOGY
  • FIGURE 18. THERAPEUTIC VACCINES MARKET FOR ALLOGENEIC VACCINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. THERAPEUTIC VACCINES MARKET FOR AUTOLOGOUS VACCINE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 21. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 23. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 24. COMPETITIVE DASHBOARD
  • FIGURE 25. COMPETITIVE HEATMAP: THERAPEUTIC VACCINES MARKET
  • FIGURE 26. TOP PLAYER POSITIONING, 2024
  • FIGURE 27. AGENUS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 28. AGENUS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 29. AGENUS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 30. ARGOS THERAPEUTICS, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 31. ARGOS THERAPEUTICS, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 32. ARGOS THERAPEUTICS, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 33. CELLDEX THERAPEUTICS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 34. CELLDEX THERAPEUTICS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 35. CELLDEX THERAPEUTICS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 36. DENDREON PHARMACEUTICALS LLC: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 37. DENDREON PHARMACEUTICALS LLC: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 38. DENDREON PHARMACEUTICALS LLC: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 39. GSK PLC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 40. GSK PLC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 41. GSK PLC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 42. MERCK AND CO. INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 43. MERCK AND CO. INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 44. MERCK AND CO. INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 45. NOVARTIS AG: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 46. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 47. NOVARTIS AG: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 48. PFIZER, INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 49. PFIZER, INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 50. PFIZER, INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 51. ASTRAZENECA: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 52. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 53. ASTRAZENECA: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 54. BIONTECH SE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 55. BIONTECH SE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 56. BIONTECH SE: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Global Therapeutic Vaccines Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved